(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Edema D004487 152 associated lipids
Exostoses, Multiple Hereditary D005097 3 associated lipids
Fasciitis D005208 2 associated lipids
Fatigue D005221 10 associated lipids
Fibrosarcoma D005354 8 associated lipids
Gallbladder Diseases D005705 3 associated lipids
Hemolysis D006461 131 associated lipids
Hepatitis D006505 11 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperlipoproteinemia Type II D006938 22 associated lipids
Hyperlipidemias D006949 73 associated lipids
Hyperlipoproteinemias D006951 15 associated lipids
Hyperlipoproteinemia Type III D006952 4 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Inflammation D007249 119 associated lipids
Influenza, Human D007251 11 associated lipids
Keloid D007627 12 associated lipids
Leukemia D007938 74 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Sarpietro MG et al. Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. 2011 Int J Pharm pmid:21219999
Brasser AJ et al. Presence of wax esters and squalene in human saliva. 2011 Arch. Oral Biol. pmid:21247555
Arguedas A et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. 2011 Hum Vaccin pmid:21285531
Manuel O et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. 2011 Clin. Infect. Dis. pmid:21288852
Alghisi F et al. Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. 2011 Thorax pmid:21228426
Decaro N et al. Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. 2011 Vaccine pmid:21272607
Pariani E et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. 2011 Vaccine pmid:21974995
Andrews NJ et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. 2011 Vaccine pmid:21875635
Vesikari T et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. 2011 N. Engl. J. Med. pmid:21995388
Niehaus TD et al. Identification of unique mechanisms for triterpene biosynthesis in Botryococcus braunii. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21746901
Bildstein L et al. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. 2011 Eur J Pharm Biopharm pmid:21784150
Della Cioppa G et al. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. 2011 Vaccine pmid:21906647
Fox CB et al. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. 2011 Vaccine pmid:21906648
Zuccotti GV et al. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. 2011 Diabet. Med. pmid:21916971
Meyer K et al. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. 2011 PLoS ONE pmid:21887300
Broeders NE et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. 2011 Clin J Am Soc Nephrol pmid:21921153
Weyermann C et al. Initial results on the composition of fingerprints and its evolution as a function of time by GC/MS analysis. 2011 J. Forensic Sci. pmid:20707835
Tabache F et al. Acute polyarthritis after influenza A (H1N1) immunization. 2011 Joint Bone Spine pmid:21444232
Sun Y et al. A reproducible in-vivo model of lymphatic malformation in rats. 2011 J. Comp. Pathol. pmid:21419420
Meier S et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. 2011 Vaccine pmid:21419775
Réjiba S et al. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. 2011 Nanomedicine pmid:21419876
Banzhoff A et al. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. 2011 Hum Vaccin pmid:21422814
Parretta E et al. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. 2011 Vaccine pmid:21406267
Ambike A et al. Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane. 2011 Langmuir pmid:21413743
Montana M et al. Safety review: squalene and thimerosal in vaccines. 2010 Nov-Dec Therapie pmid:21176760
Smentek L and Hess BA Compelling computational evidence for the concerted cyclization of the ABC rings of hopene from protonated squalene. 2010 J. Am. Chem. Soc. pmid:21080653
Fragapane E et al. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. 2010 Clin. Vaccine Immunol. pmid:20810680
Esposito S et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. 2010 Vaccine pmid:20888873
Ansaldi F et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. 2010 Vaccine pmid:20433807
Pili B et al. Interaction of a new anticancer prodrug, gemcitabine-squalene, with a model membrane: coupled DSC and XRD study. 2010 Biochim. Biophys. Acta pmid:20435013
Gylling H et al. Insulin sensitivity regulates cholesterol metabolism to a greater extent than obesity: lessons from the METSIM Study. 2010 J. Lipid Res. pmid:20436182
Chen G et al. Optimization of nitrogen source for enhanced production of squalene from thraustochytrid Aurantiochytrium sp. 2010 N Biotechnol pmid:20412873
Xiao L et al. The effect of squalane-dissolved fullerene-C60 on adipogenesis-accompanied oxidative stress and macrophage activation in a preadipocyte-monocyte co-culture system. 2010 Biomaterials pmid:20488530
Carmona A et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. 2010 Vaccine pmid:20600478
Caligiani A et al. Characterization of a potential nutraceutical ingredient: pomegranate (Punica granatum L.) seed oil unsaponifiable fraction. 2010 Plant Foods Hum Nutr pmid:20607413
Zhao RY et al. Cloning and characterization of squalene synthase gene from Fusarium fujikuroi (Saw.) Wr. 2010 J. Ind. Microbiol. Biotechnol. pmid:20585832
De Luca C and Valacchi G Surface lipids as multifunctional mediators of skin responses to environmental stimuli. 2010 Mediators Inflamm. pmid:20981292
Tsuchiya M et al. Cholesterol biosynthesis pathway intermediates and inhibitors regulate glucose-stimulated insulin secretion and secretory granule formation in pancreatic beta-cells. 2010 Endocrinology pmid:20685866
Camilloni B et al. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. 2010 Vaccine pmid:20846530
Ihara T [Evaluation of alum-adjuvanted whole virus influenza vaccine and future aspects of influenza A (H1N1) 2009 vaccine]. 2010 Uirusu pmid:20848866
Sere YY et al. A Saccharomyces cerevisiae strain unable to store neutral lipids is tolerant to oxidative stress induced by α-synuclein. 2010 Free Radic. Biol. Med. pmid:20850523
Vesikari T et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. 2010 Pediatrics pmid:20819892
Pili B et al. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation. 2010 Nanoscale pmid:20820745
Camera E et al. Comprehensive analysis of the major lipid classes in sebum by rapid resolution high-performance liquid chromatography and electrospray mass spectrometry. 2010 J. Lipid Res. pmid:20719760
Watanabe T et al. Novel pyrrole- and 1,2,3-triazole-based 2,3-oxidosqualene cyclase inhibitors. 2010 Bioorg. Med. Chem. Lett. pmid:20728352
Ray R et al. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. 2010 J. Infect. Dis. pmid:20677942
Nováková Z et al. Effects of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor pravastatin on membrane lipids and membrane associated functions of Methanothermobacter thermautotrophicus. 2010 Folia Microbiol. (Praha) pmid:20680571
Bate J et al. Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. 2010 Clin. Infect. Dis. pmid:21067352
Madhun AS et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. 2010 Vaccine pmid:21034828
Kato S et al. Clinical evaluation of fullerene-C60 dissolved in squalane for anti-wrinkle cosmetics. 2010 J Nanosci Nanotechnol pmid:21137794